FDA, Industry Seek Temporary Endpoint For Assessing Ulcerative Colitis Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Panelists at an agency workshop discussed tweaks to the Mayo Clinic Score while patient-reported outcome instruments are being developed in an initiative to create an improved ulcerative colitis endpoint.